The Charleston HFpEF Conference focuses on the diagnostic and treatment challenges of heart failure with preserved ejection fraction. The program examines phenotyping, diastolic dysfunction, cardiometabolic disease, and the role of obesity, alongside sessions on drug therapy, diuretics, and remote monitoring. Cardiac amyloidosis, hypertrophic cardiomyopathy, pulmonary hypertension, iron deficiency, and advanced kidney disease receive dedicated attention. Directed by Sheldon Litwin, MD, the meeting also considers devices, imaging, artificial intelligence, multidisciplinary clinics, and shared treatment decisions. It is intended for cardiologists, heart failure specialists, advanced practice providers, and other clinicians who want a focused review of HFpEF rather than a general heart failure survey.
Original meeting: July 18–20, 2025, Hyatt Place Hotel, Charleston, South Carolina. Institution: Medical University of South Carolina.
Learning Objectives
At the completion of this conference, participants should be able to:
- Review the latest evidence on the optimal choices of diuretics in heart failure.
- Discuss new approaches to giving advice about sodium and fluid restriction in patients with heart failure.
- Effectively prescribe medications for weight management in patients with HFpEF.
- Engage in shared decision making with patients about the value of newer treatments.
- Discuss the mechanisms of diastolic dysfunction in patients with HFpEF.
- Design and implement a HF clinic for follow-up of recently hospitalized HF patients.
Conference Director
Sheldon Litwin, MD, FACC, FAHA, FASE, FSCCT
Conference Director
Professor of Medicine, Cardiology and Radiology
Director of Echocardiography
Medical University of South Carolina
The official MUSC conference materials identify Dr. Sheldon Litwin as Conference Director.
Selected 2025 Faculty and Sessions
The published agenda includes presentations from specialists such as:
- Michael Zile, MD — Fibrosis in HFpEF
- Daniel Silverman, MD — Challenging HFpEF Cases
- Andrew Sauer, MD — Remote Monitoring in HFpEF
- Vishal Rao, MD — HFpEF Phenotyping
- Gregory Lewis, MD — Iron Deficiency in Heart Failure
- Nosheen Reza, MD — Hypertrophic Cardiomyopathy
- Parag Goyal, MD, MSc — Polypharmacy in HFpEF
- Tom Cascino, MD, MSc — Pulmonary Hypertension and Comorbidities
- Michele Esposito, MD — Device Therapies in HFpEF
- Ryan Tedford, MD — Top HFpEF Papers
- Jeffrey Teuteberg, MD — Heart Transplantation and HFpEF
- Sheldon Litwin, MD — HFpEF as a Metabolic Disease
- Monica Mukherjee, MD, MPH — Autoimmune Disease and HFpEF
- Muthiah Vaduganathan, MD — MRAs in HFpEF
- Hanna Gaggin, MD, MPH — Transthyretin Cardiac Amyloidosis
- Yogesh Reddy, MBBS — SGLT2 Inhibitors and GLP-1 Agonists in HFpEF
These faculty and session topics are listed in the published 2025 MUSC agenda.
Topics
-
Reaching a New Peak – Results of SUMMIT and GLP-1 Agonists in HFpEF
-
No Longer Limited Options – New and Emerging Treatments for HFpEF
-
Key Issues Surrounding Remote Monitoring in HFpEF in 2025 – Implementation, Pressure vs. Volume, Biomarkers vs. Hemodynamics
-
Phenotyping Heart Failure with Preserved Ejection Fraction – How Do We Make It Clinically Relevant
-
Etiology, Evaluation and Management of Iron Deficiency in Heart Failure
-
The Original HFpEF Contemporary Approach to Diagnosis and Treatment of Hypertrophic Cardiomyopathy (tập tin Word)
-
The Perils and Pearls of Polypharmacy in HFpEF – Clinical and Financial Toxicity
-
Is it Cardiac, Pulmonary, or Both The Challenge of Diagnosing and Treating PH with Comorbidities
-
The Emerging Role of Device Therapies for HFpEF
-
Top HFpEF Paper of the Year
-
Should We Transplant Patients with HFpEF
-
HFpEF is a Metabolic Disease – Changing Treatment Paradigms
-
From Inflammation to Dysfunction – Autoimmune Disease as a Substrate for HFpEF
-
Mortimer, We’re Back – The Re-Emergence of MRA’s in HFpEF
-
The Latest in Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis – Stopping the Epidemic
-
How Do SGLT2 Inhibitors and GLP1 Agonists Really Work in Patients with HFpEF
-
Pearls Learned from Running an APP Lead Heart Failure Clinic
-
Artificial Intelligence for the Diagnosis and Management of HFpEF
-
Post-PE Syndrome – HFpEF Mimicker – How to Distinguish and Treat
-
Cardiac MRI for HFpEF; Can We Help
-
Update on Optimizing Diuretic Therapy in Patients with HFpEF
-
Defining HFpEF – Is the Wedge Still the Cutting Edge
-
-Omic Precision Medicine for HFpEF
-
Management of HFpEF In Patients with Advanced Kidney Disease and End-Stage Renal Disease
-
Panel Discussion – How Do We Continue & Speed Up The Current Progress That Has Been Made In The Treatment Of HFpEF Over
The topic list describes the educational material and does not establish a separate video for every agenda entry. The hypertrophic cardiomyopathy item is marked as a Word document in the supplied list. Provider registration, live participation, streaming access, MOC credit, certificates, apps, accounts, and post-course platform access are not included with independently supplied study files.



